St John Skilton, PhD


Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma Development

St John Skilton, PhD, vice president of product strategy and marketing at Protein Metrics, takes a deep dive into how the development of biosimilars is evolving and how tools, such as mass spectrometry, can help companies keep up with advancing technology.

Robert Zutaut, RPh


Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis Biosimilars

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.

Wayne Winegarden, PhD


Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.

Ha Kung Wong
Ha Kung Wong, JD


Contributor: The Trouble With IP for Digital Health and Precision Medicine

Two experts in biosimilar intellectual property (IP) law break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.

Kostas Botsoglou, MD


Resources for Patients and Providers on Adalimumab Biosimilars

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

Juliana M. Reed


Americans Say Drug Costs Are Too High, and They Are Right

The executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.

Ashley Gallagher


Insights From Cencora's Dr Lakesha Farmer: Innovative Biosimilar Adoption Strategies

Lakesha Farmer, PharmD, MBA, from Cencora discusses innovative pricing and reimbursement models incentivizing biosimilar adoption and competitiveness, including dual pricing strategies and the Mark Cuban Cost Plus Program, while highlighting potential impacts on patient assistance programs.

Ted Mathias, JD


Opinion: Purple Book Patent Listings Are Only a First Step

Intellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.

Craig Burton


Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition

In response to another opinion piece, Craig Burton, from the Association for Accessible Medicines, argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result.

Amanda DeMarzo, PharmD, MBA, PACS


The Pandemic's Multilevel Effect on Patient Access

Coronavirus disease 2019 altered the workflow in all areas of the health care and life sciences industries, and the FDA was not exempt from pandemic-induced upheaval.

Tony Hagen


AmerisourceBergen Rep Previews the Year Ahead for Biosimilars: What’s Coming Down the Pipeline in 2022?

Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.

Steven Lucio, PharmD, BCPS


Understanding the Risks, Opportunities, and Prospects of Biosimilars in 2020 and Beyond

Hurdles to a vibrant biosimilar market are not as insurmountable as they appear.

Skylar Jeremias


FDA Approves First Eculizumab Biosimilar

The FDA approved Bkemv (eculizumab-aeeb) as the first biosimilar to Soliris (eculizumab) for 2 rare diseases. It was also approved with interchangeability.

Ron Lanton


New Rule: Transition to BLA Pathway Is Complete

As of today, the FDA has completed a 10-year process to bring a wider set of biologics under the biologics license pathway for approval.

Stan R. Mehr


Drug Couponing: Better or Worse for Biosimilars?

Payers will have to carefully mull limited options.

© 2024 MJH Life Sciences

All rights reserved.